Cargando…

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant

By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Par...

Descripción completa

Detalles Bibliográficos
Autores principales: Khong, Ka-Wa, Liu, Danlei, Leung, Ka-Yi, Lu, Lu, Lam, Hoi-Yan, Chen, Linlei, Chan, Pui-Chun, Lam, Ho-Ming, Xie, Xiaochun, Zhang, Ruiqi, Fan, Yujing, To, Kelvin Kai-Wang, Chen, Honglin, Yuen, Kwok-Yung, Chan, Kwok-Hung, Hung, Ivan Fan-Ngai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877145/
https://www.ncbi.nlm.nih.gov/pubmed/35214619
http://dx.doi.org/10.3390/vaccines10020160
_version_ 1784658341501337600
author Khong, Ka-Wa
Liu, Danlei
Leung, Ka-Yi
Lu, Lu
Lam, Hoi-Yan
Chen, Linlei
Chan, Pui-Chun
Lam, Ho-Ming
Xie, Xiaochun
Zhang, Ruiqi
Fan, Yujing
To, Kelvin Kai-Wang
Chen, Honglin
Yuen, Kwok-Yung
Chan, Kwok-Hung
Hung, Ivan Fan-Ngai
author_facet Khong, Ka-Wa
Liu, Danlei
Leung, Ka-Yi
Lu, Lu
Lam, Hoi-Yan
Chen, Linlei
Chan, Pui-Chun
Lam, Ho-Ming
Xie, Xiaochun
Zhang, Ruiqi
Fan, Yujing
To, Kelvin Kai-Wang
Chen, Honglin
Yuen, Kwok-Yung
Chan, Kwok-Hung
Hung, Ivan Fan-Ngai
author_sort Khong, Ka-Wa
collection PubMed
description By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses.
format Online
Article
Text
id pubmed-8877145
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88771452022-02-26 Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant Khong, Ka-Wa Liu, Danlei Leung, Ka-Yi Lu, Lu Lam, Hoi-Yan Chen, Linlei Chan, Pui-Chun Lam, Ho-Ming Xie, Xiaochun Zhang, Ruiqi Fan, Yujing To, Kelvin Kai-Wang Chen, Honglin Yuen, Kwok-Yung Chan, Kwok-Hung Hung, Ivan Fan-Ngai Vaccines (Basel) Article By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses. MDPI 2022-01-21 /pmc/articles/PMC8877145/ /pubmed/35214619 http://dx.doi.org/10.3390/vaccines10020160 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Khong, Ka-Wa
Liu, Danlei
Leung, Ka-Yi
Lu, Lu
Lam, Hoi-Yan
Chen, Linlei
Chan, Pui-Chun
Lam, Ho-Ming
Xie, Xiaochun
Zhang, Ruiqi
Fan, Yujing
To, Kelvin Kai-Wang
Chen, Honglin
Yuen, Kwok-Yung
Chan, Kwok-Hung
Hung, Ivan Fan-Ngai
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
title Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
title_full Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
title_fullStr Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
title_full_unstemmed Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
title_short Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
title_sort antibody response of combination of bnt162b2 and coronavac platforms of covid-19 vaccines against omicron variant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877145/
https://www.ncbi.nlm.nih.gov/pubmed/35214619
http://dx.doi.org/10.3390/vaccines10020160
work_keys_str_mv AT khongkawa antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT liudanlei antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT leungkayi antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT lulu antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT lamhoiyan antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT chenlinlei antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT chanpuichun antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT lamhoming antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT xiexiaochun antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT zhangruiqi antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT fanyujing antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT tokelvinkaiwang antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT chenhonglin antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT yuenkwokyung antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT chankwokhung antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant
AT hungivanfanngai antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant